Clinical trials
Phase 1 Lupus Erythematosus, Systemic trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 2 |
| AstraZeneca | 2 |
| Bristol-Myers Squibb | 2 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
| Novartis Pharmaceuticals | 2 |
| UCB Pharma | 2 |
| CRISPR Therapeutics | 1 |
| Hoffmann-La Roche | 1 |
| Janssen Research & Development, LLC | 1 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 18 |
| Autoimmune Diseases | 6 |
| Arthritis, Rheumatoid | 5 |
| Myositis | 5 |
| Lupus Nephritis | 4 |
| Scleroderma, Systemic | 4 |
| Connective Tissue Diseases | 3 |
| Dermatomyositis | 3 |
| Scleroderma, Diffuse | 3 |
| Immune System Diseases | 2 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.